Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 5, 1999, Pages 433-438

  Kasper, Bernd ^a   Fruehauf, Stefan ^b   Schiedlmeier, Bernd ^a   Buchdunger, Elisabeth ^c   Ho, Anthony D ^b   Jens Zeller, W ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

CML treatment; Mobilized peripheral blood progenitor cells; Purging; Stroma dependent long term cultures; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CELL CULTURE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; COLONY FORMING CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEM CELL;

ANTINEOPLASTIC AGENTS; COCULTURE TECHNIQUES; COLONY-FORMING UNITS ASSAY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 0032859309     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051001     Document Type: Article

References (27)

1. bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82: 3524
2. 2. Breems DA, Blokland EA, Neben S, Ploemacher RE (1994) Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 8: 1095
3. 3. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56: 100
4. 4. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ (1997) CGP57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood 90: 4947
5. 5. Cortes JE, Talpaz M, Kantarjian H (1996) Chronic myelogenous leukemia: a review. Am J Med 100: 555
6. 6. Cotteret S, Belloc F, Jaquemin G, Lacombe F, Reiffers J, Bernard P (1998) BCR-ABL tyrosine kinase activity is responsible for the apoptosis resistant phenotype of K562 cells by blocking an event independent of the caspase activation pathway. Blood 92: 371a
7. 7. Cox MC, Maffei L, Buffolino S, Del Poeta G, Venditti A, Cantonetti M, Aronica G, Aquilina P, Masi M, Amadori S (1998) A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias. Am J Clin Pathol 109: 24
8. 8. Cross NC, Hughes TP, Feng L, O'Shea P, Bungey J, Marks DI, Ferrant P, Martiat P, Goldman JM (1993) Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 84: 67
9. 9. Deininger M, Goldman JM, Melo JV (1997) The induction of apoptosis in CML cells exposed to the tyrosine kinase inhibitor CGP57148B is associated with altered gene transcription. Blood 90: 83a
10. 10. Dexter TM, Allen TD, Lajtha LG (1977) Conditions controlling the proliferation of hematopoietic stem cells in vitro. J Cell Physiol 91: 335
11. 11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of bcr/abl positive cells. Nat Med 2: 561
12. 12. Druker BJ, Sawyers CL, Talpaz M, Resta D, Peng B, Ford J (1998) Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP57148, in Interferon refractory chronic myelogenous leukemia patients. Blood 92: 252a
13. 13. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C (1993) Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Res 53: 1735
14. 14. Gambacorti-Passerini C, Coutre P le, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Blondi A, Corneo GM, Belotti D, Pogliani E, Lydon NB (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis. Blood Cells Mol Dis 23: 380
15. 15. Geissler JF, Roesel J, Meyer T, Trinks UP, Traxler P, Lydon NB (1992) Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res 52: 4492
16. 16. Hehlmann R, Heimpel H (1996) Current aspects of drug therapy in Philadelphia-positive CML: correlation of tumor burden with survival. Leuk Lymphoma 22: 161
17. 17. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Griesshammer M, Bergmann L, Essers U, Falge C, Queisser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow P v., Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, the German CML Study Group (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84: 4064
18. 18. Hehlmann R, Ansari H, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Reiter A, Hochhaus A, the German CML Study Group (1997) Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. Br J Haematol 97: 76
19. 19. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122: 254
20. 20. Klein A de, Kessel AG van, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300: 765
21. 21. Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267: 1782
22. 22. Lugo TG, Pendergast AM, Müller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr/abl oncogene products. Science 247: 1079
23. 23. Mahon FX, Pigeonnier-Lagarde V, Chahine H, Barbot C, Jazwiec B, Ripoche J, Reiffers J (1997) Ex vivo cytokine expansion of peripheral blood 5-fluoruracil-treated CD34-positive chronic myeloid leukaemia cells increases the selection of Ph-negative cells. Br J Haematol 98: 467
24. 24. Petzer AL, Eaves CJ, Barnett MJ, Eaves AC (1997) Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood 90: 64
25. 25. Schulze E, Krahl R, Thalmeier K, Heibig W (1995) Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells. Exp Hematol 23: 1649
26. 26. Thijsen SF, Schuurhuis GJ, Oostveen JW van, Theijsmeijer AP, Langenhuijsen MM, Ossenkoppele GJ (1997) Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR. Leukemia 11: 301
27. 27. Yaish P, Gazit A, Gilon C, Levitzki A (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242: 933